U.K. Cost Regulator May Reject Gilead’s Sovaldi Treatment
This article is for subscribers only.
The U.K.’s health-cost regulator said it may reject Gilead Sciences Inc.’s $60,000 hepatitis C drug Sovaldi, and asked for more data before deciding whether the British government should pay for the treatment.
Gilead lacks evidence on Sovaldi for some patient groups, the National Institute for Health and Care Excellence said in an e-mailed statement today. The agency said it has asked Foster City, California-based Gilead for more information, including about Sovaldi’s cost-effectiveness in patients with and without liver damage and HIV.